tradingkey.logo

硕腾

ZTS
127.170USD
+0.320+0.25%
收盘 01/09, 16:00美东报价延迟15分钟
56.14B总市值
21.41市盈率 TTM

硕腾

127.170
+0.320+0.25%

关于 硕腾 公司

Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).

硕腾简介

公司代码ZTS
公司名称Zoetis Inc
上市日期Feb 01, 2013
CEOPeck (Kristin C)
员工数量13800
证券类型Ordinary Share
年结日Feb 01
公司地址10 Sylvan Way
城市PARSIPPANY
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家United States of America
邮编07054
电话19738227000
网址https://www.zoetis.com/
公司代码ZTS
上市日期Feb 01, 2013
CEOPeck (Kristin C)

硕腾公司高管

名称
名称/职务
职务
持股
持股变动
Ms. Kristin C. Peck
Ms. Kristin C. Peck
Chief Executive Officer, Director
Chief Executive Officer, Director
95.01K
+18.00%
Mr. Gregory (Greg) Norden
Mr. Gregory (Greg) Norden
Independent Director
Independent Director
16.95K
+1843.00%
Ms. Louise M. Parent
Ms. Louise M. Parent
Independent Director
Independent Director
15.26K
--
Mr. Sanjay Khosla
Mr. Sanjay Khosla
Independent Director
Independent Director
9.81K
--
Dr. Robert J. (Rob) Polzer, Ph.D.
Dr. Robert J. (Rob) Polzer, Ph.D.
Executive Vice President, President - Research and Development
Executive Vice President, President - Research and Development
6.19K
+24.00%
Ms. Rimma Driscoll
Ms. Rimma Driscoll
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
5.19K
+397.00%
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Independent Director
Independent Director
2.82K
+961.00%
Mr. Jamie Brannan
Mr. Jamie Brannan
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
2.59K
+418.00%
Mr. Keith Sarbaugh
Mr. Keith Sarbaugh
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
2.04K
+990.00%
Mr. Nicholas (Nick) Ashton
Mr. Nicholas (Nick) Ashton
Executive Vice President, President - Global Manufacturing and Supply
Executive Vice President, President - Global Manufacturing and Supply
1.09K
+448.00%
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Kristin C. Peck
Ms. Kristin C. Peck
Chief Executive Officer, Director
Chief Executive Officer, Director
95.01K
+18.00%
Mr. Gregory (Greg) Norden
Mr. Gregory (Greg) Norden
Independent Director
Independent Director
16.95K
+1843.00%
Ms. Louise M. Parent
Ms. Louise M. Parent
Independent Director
Independent Director
15.26K
--
Mr. Sanjay Khosla
Mr. Sanjay Khosla
Independent Director
Independent Director
9.81K
--
Dr. Robert J. (Rob) Polzer, Ph.D.
Dr. Robert J. (Rob) Polzer, Ph.D.
Executive Vice President, President - Research and Development
Executive Vice President, President - Research and Development
6.19K
+24.00%
Ms. Rimma Driscoll
Ms. Rimma Driscoll
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
5.19K
+397.00%

收入明细

单位: USD更新时间: 1月6日 周二
单位: USD更新时间: 1月6日 周二
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Parasiticides
564.00M
23.50%
Vaccines
496.00M
20.67%
Dermatology
472.00M
19.67%
Anti-infectives
284.00M
11.83%
Pain and sedation
204.00M
8.50%
其他
380.00M
15.83%
地区USD
名称
营收
占比
United States
1.32B
55.08%
Other emerging markets
228.00M
9.50%
Other Developed
164.00M
6.83%
Brazil
100.00M
4.17%
Australia
87.00M
3.62%
其他
499.00M
20.79%
业务
地区
业务USD
名称
营收
占比
Parasiticides
564.00M
23.50%
Vaccines
496.00M
20.67%
Dermatology
472.00M
19.67%
Anti-infectives
284.00M
11.83%
Pain and sedation
204.00M
8.50%
其他
380.00M
15.83%

股东统计

更新时间: 1月10日 周六
更新时间: 1月10日 周六
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
10.84%
BlackRock Institutional Trust Company, N.A.
5.17%
State Street Investment Management (US)
4.46%
State Farm Insurance Companies
3.83%
Geode Capital Management, L.L.C.
2.53%
其他
73.17%
持股股东
持股股东
占比
The Vanguard Group, Inc.
10.84%
BlackRock Institutional Trust Company, N.A.
5.17%
State Street Investment Management (US)
4.46%
State Farm Insurance Companies
3.83%
Geode Capital Management, L.L.C.
2.53%
其他
73.17%
股东类型
持股股东
占比
Investment Advisor
49.16%
Investment Advisor/Hedge Fund
32.07%
Research Firm
4.42%
Insurance Company
3.92%
Bank and Trust
2.63%
Pension Fund
2.55%
Hedge Fund
1.56%
Sovereign Wealth Fund
1.25%
Family Office
0.15%
其他
2.30%

机构持股

更新时间: 1月1日 周四
更新时间: 1月1日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q4
3273
437.10M
99.18%
-8.45M
2025Q3
3275
435.62M
98.29%
-1.39M
2025Q2
3277
434.35M
98.00%
-1.58M
2025Q1
3284
432.42M
97.12%
-4.21M
2024Q4
3199
430.60M
96.14%
-9.58M
2024Q3
3090
434.14M
95.81%
-13.19M
2024Q2
3062
437.75M
95.94%
-9.33M
2024Q1
3060
439.45M
96.16%
-2.63M
2023Q4
3074
438.13M
95.43%
-2.08M
2023Q3
2966
434.04M
94.28%
-3.00M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
47.78M
10.84%
+5.68M
+13.48%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
22.80M
5.17%
+144.71K
+0.64%
Sep 30, 2025
State Street Investment Management (US)
19.65M
4.46%
-89.97K
-0.46%
Sep 30, 2025
State Farm Insurance Companies
16.87M
3.83%
+21.40K
+0.13%
Sep 30, 2025
Geode Capital Management, L.L.C.
11.14M
2.53%
+57.14K
+0.52%
Sep 30, 2025
Wellington Management Company, LLP
8.54M
1.94%
-348.26K
-3.92%
Sep 30, 2025
Polen Capital Management, LLC
7.52M
1.71%
-904.12K
-10.74%
Sep 30, 2025
Morgan Stanley Investment Management Ltd. (UK)
7.48M
1.7%
+722.07K
+10.69%
Sep 30, 2025
Wells Fargo Advisors
5.64M
1.28%
-193.47K
-3.32%
Sep 30, 2025
Norges Bank Investment Management (NBIM)
5.19M
1.18%
+131.36K
+2.60%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
ProShares Pet Care ETF
9.4%
VanEck Pharmaceutical ETF
9.02%
VanEck Agribusiness ETF
7.81%
iShares U.S. Pharmaceuticals ETF
4.26%
Honeytree US Equity ETF
3.86%
First Trust NASDAQ Pharmaceuticals ETF
3.58%
Polen Capital Global Growth ETF
3.35%
State Street SPDR S&P Pharmaceuticals ETF
2.51%
AAM Sawgrass US Large Cap Quality Growth ETF
2.47%
Themes US R&D Champions ETF
1.96%
查看更多
ProShares Pet Care ETF
占比9.4%
VanEck Pharmaceutical ETF
占比9.02%
VanEck Agribusiness ETF
占比7.81%
iShares U.S. Pharmaceuticals ETF
占比4.26%
Honeytree US Equity ETF
占比3.86%
First Trust NASDAQ Pharmaceuticals ETF
占比3.58%
Polen Capital Global Growth ETF
占比3.35%
State Street SPDR S&P Pharmaceuticals ETF
占比2.51%
AAM Sawgrass US Large Cap Quality Growth ETF
占比2.47%
Themes US R&D Champions ETF
占比1.96%

分红派息

近5年累计派现 2.56B 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Dec 11, 2025
ZTS.NB Interim Cash Dividend of gross USD 0.53 paid on Mar 03, 2026 going ex on Jan 20, 2026
Jan 20, 2026
Mar 03, 2026
Jan 20, 2026
Oct 09, 2025
ZTS.NB Final Cash Dividend of gross USD 0.5 paid on Dec 02, 2025 going ex on Oct 31, 2025
Oct 31, 2025
Dec 02, 2025
Oct 31, 2025
May 21, 2025
ZTS.NB Interim Cash Dividend of gross USD 0.5 paid on Sep 03, 2025 going ex on Jul 18, 2025
Jul 18, 2025
Sep 03, 2025
Jul 18, 2025
Feb 06, 2025
ZTS.NB Interim Cash Dividend of gross USD 0.5 paid on Jun 03, 2025 going ex on Apr 21, 2025
Apr 21, 2025
Jun 03, 2025
Apr 21, 2025
Dec 12, 2024
ZTS.NB Interim Cash Dividend of gross USD 0.5 paid on Mar 04, 2025 going ex on Jan 21, 2025
Jan 21, 2025
Mar 04, 2025
Jan 21, 2025
Oct 10, 2024
ZTS.NB Final Cash Dividend of gross USD 0.432 paid on Dec 03, 2024 going ex on Oct 31, 2024
Oct 31, 2024
Dec 03, 2024
Oct 31, 2024
May 22, 2024
ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Sep 04, 2024 going ex on Jul 18, 2024
Jul 18, 2024
Sep 04, 2024
Jul 18, 2024
Feb 06, 2024
ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Jun 04, 2024 going ex on Apr 18, 2024
Apr 19, 2024
Jun 04, 2024
Apr 18, 2024
Dec 07, 2023
ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Mar 01, 2024 going ex on Jan 18, 2024
Jan 19, 2024
Mar 01, 2024
Jan 18, 2024
Oct 12, 2023
ZTS.NB Final Cash Dividend of gross USD 0.375 paid on Dec 01, 2023 going ex on Oct 31, 2023
Nov 01, 2023
Dec 01, 2023
Oct 31, 2023
查看更多

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

硕腾的前五大股东是谁?

硕腾 的前五大股东如下:
The Vanguard Group, Inc.持有股份:47.78M,占总股份比例:10.84%。
BlackRock Institutional Trust Company, N.A.持有股份:22.80M,占总股份比例:5.17%。
State Street Investment Management (US)持有股份:19.65M,占总股份比例:4.46%。
State Farm Insurance Companies持有股份:16.87M,占总股份比例:3.83%。
Geode Capital Management, L.L.C.持有股份:11.14M,占总股份比例:2.53%。

硕腾的前三大股东类型是什么?

硕腾 的前三大股东类型分别是:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)

有多少机构持有硕腾(ZTS)的股份?

截至2025Q4,共有3273家机构持有硕腾的股份,合计持有的股份价值约为437.10M,占公司总股份的99.18%。与2025Q3相比,机构持股有所增加,增幅为0.89%。

哪个业务部门对硕腾的收入贡献最大?

在FY2025Q3,Parasiticides业务部门对硕腾的收入贡献最大,创收564.00M,占总收入的23.50%。
KeyAI